(NASDAQ: ILMN) Illumina's forecast annual revenue growth rate of 5.99% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.78%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.47%.
Illumina's revenue in 2026 is $4,493,000,000.On average, 24 Wall Street analysts forecast ILMN's revenue for 2026 to be $711,663,000,000, with the lowest ILMN revenue forecast at $674,819,000,000, and the highest ILMN revenue forecast at $736,578,000,000. On average, 24 Wall Street analysts forecast ILMN's revenue for 2027 to be $756,208,000,000, with the lowest ILMN revenue forecast at $707,888,000,000, and the highest ILMN revenue forecast at $800,149,000,000.
In 2028, ILMN is forecast to generate $809,360,000,000 in revenue, with the lowest revenue forecast at $745,940,000,000 and the highest revenue forecast at $896,185,000,000.